跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
诺和佳 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Insulin Degludec and Insulin Aspart Injection
Approved
生物制品
Insulin Degludec and Insulin Aspart Injection
Novo Nordisk A/S
🇨🇳 National Medical Products Administration
Approval Date
Apr 10, 2024
Approval ID
8aKPkaQgpvN
Company
Novo Nordisk A/S
Type
生物制品
Approval Details
Approval Id
8aKPkaQgpvN
Approval Number
国药准字SJ20190028
Generic Name
德谷门冬双胰岛素注射液
Generic Name En
Insulin Degludec and Insulin Aspart Injection
Trade Name
诺和佳
Drug Type
生物制品
Dosage Form
注射剂
Strength
3ml:300单位(畅充)
Reg Date
2024-04-10
Expired Date
2029-04-09
Company Name
Novo Nordisk A/S
Production Company Name
Novo Nordisk A/S
Company Detail Path
/organization/novo-nordisk-a-s
Production Company Detail Path
/organization/novo-nordisk-a-s
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Apr 10, 2024
Approval ID
8aKPkaQgpvN
Type
生物制品
Back to NMPA Approvals
